Last data update: Jan 21, 2025. (Total: 48615 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Kasper AM[original query] |
---|
Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015)
Kasper AM , Ridpath AD , Gerona RR , Cox R , Galli R , Kyle PB , Parker C , Arnold JK , Chatham-Stephens K , Morrison MA , Olayinka O , Preacely N , Kieszak SM , Martin C , Schier JG , Wolkin A , Byers P , Dobbs T . Clin Toxicol (Phila) 2018 57 (1) 1-9 STUDY OBJECTIVES: In April 2015, a multistate outbreak of illness linked to synthetic cannabinoid (SC) use was unprecedented in magnitude and severity. We identified Mississippi cases in near-real time, collected information on cases to characterize the outbreak, and identified the causative SC. METHODS: A case was defined as any patient of a Mississippi healthcare facility who was suspected of SC use and presenting with >/=2 of the following symptoms: sweating, severe agitation, or psychosis during April 2-May 3, 2015. Clinicians reported cases to the Mississippi Poison Control Center (MPCC). We used MPCC data to identify cases at the University of Mississippi Medical Center (UMMC) to characterize in further detail, including demographics and clinical findings. Biologic samples were tested for known and unknown SCs by liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF/MS). RESULTS: Clinicians reported 721 cases (11 deaths) statewide; 119 (17%) were UMMC patients with detailed data for further analysis. Twelve (10%) were admitted to an intensive care unit and 2 (2%) died. Aggression (32%), hypertension (33%), and tachycardia (42%) were common. SCs were identified in serum from 39/56 patients (70%); 33/39 patients (85%) tested positive for MAB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carb oxamide) or its metabolites. Compared to all patients tested for SCs, those positive for MAB-CHMINACA were more likely to have altered mental status on examination (OR = 3.3, p = .05). CONCLUSION: SC use can cause severe health effects. MAB-CHMINACA was the most commonly detected SC in this outbreak. As new SCs are created, new strategies to optimize surveillance and patient care are needed to address this evolving public health threat. |
Description of a mass poisoning in a rural district in Mozambique: The first documented bongkrekic acid poisoning in Africa
Gudo ES , Cook K , Kasper AM , Vergara A , Salomao C , Oliveira F , Ismael H , Saeze C , Mosse C , Fernandes Q , Viegas SO , Baltazar CS , Doyle TJ , Yard E , Steck A , Serret M , Falconer TM , Kern SE , Brzezinski JL , Turner JA , Boyd BL , Jani IV . Clin Infect Dis 2017 66 (9) 1400-1406 Background: On January 9, 2015, in a rural town in Mozambique, over 230 people became sick and 75 died from an illness linked to drinking pombe, a traditional alcoholic beverage. Methods: An investigation was conducted to identify cases and determine the cause of the outbreak. A case was defined as any resident of Chitima who developed any new or unexplained neurologic, gastrointestinal, or cardiovascular symptom from January 9 at 6:00 a.m. through January 12. We conducted medical record reviews; healthcare worker and community surveys; anthropological and toxicological investigations of local medicinal plants and commercial pesticides; and laboratory testing of the suspect and control pombe. Results: We identified 234 cases; 75 (32%) died and 159 recovered. Overall, 61% of cases were female (n=142), and ages ranged from 1-87 years (median: 30 years). Signs and symptoms included abdominal pain, diarrhea, vomiting, and generalized malaise. Death was preceded by psychomotor agitation and abnormal posturing. The median interval from pombe consumption to symptom onset was 16 hours. Toxic levels of bongkrekic acid (BA) were detected in the suspect pombe but not in the control pombe. Burkholderia gladioli pathovar cocovenenans, the bacteria that produces BA, was detected in the flour used to make the pombe. Conclusions: We report for the first time an outbreak of a highly lethal illness linked to BA, a deadly food-borne toxin in Africa. Given that no previous outbreaks have been recognized outside of Asia, our investigation suggests that BA might be an unrecognized cause of toxic outbreaks globally. |
Severe illness associated with reported use of synthetic cannabinoids - Mississippi, April 2015
Kasper AM , Ridpath AD , Arnold JK , Chatham-Stephens K , Morrison M , Olayinka O , Parker C , Galli R , Cox R , Preacely N , Anderson J , Kyle PB , Gerona R , Martin C , Schier J , Wolkin A , Dobbs T . MMWR Morb Mortal Wkly Rep 2015 64 (39) 1121-1122 On April 2, 2015, four patients were evaluated at the University of Mississippi Medical Center (UMMC) in Jackson, Mississippi, for agitated delirium after using synthetic cannabinoids. Over the next 3 days, 24 additional persons went to UMMC with illnesses suspected to be related to synthetic cannabinoid use; one patient died. UMMC notified the Mississippi State Department of Health, which issued a statewide alert via the Health Alert Network on April 5, requesting that health care providers report suspected cases of synthetic cannabinoid intoxication to the Mississippi Poison Control Center (MPCC). A suspected case was defined as the occurrence of at least two of the following symptoms: sweating, severe agitation, or psychosis in a person with known or suspected synthetic cannabinoid use. A second statewide alert was issued on April 13, instructing all Mississippi emergency departments to submit line lists of suspected patients to MPCC each day. By April 21, 16 days after the first alert was issued, MPCC had received reports of approximately 400 cases, including eight deaths possibly linked to synthetic cannabinoid use; in contrast, during April 2012-March 2015, the median number of telephone calls to MPCC regarding synthetic cannabinoid use was one per month (range = 0-11). The Mississippi State Department of Health, with the assistance of CDC, initiated an investigation to better characterize the outbreak, identify risk factors associated with severe illness, and prevent additional illnesses and deaths. |
- Page last reviewed:Feb 1, 2024
- Page last updated:Jan 21, 2025
- Content source:
- Powered by CDC PHGKB Infrastructure